Javascript must be enabled to continue!
Effect of Jianpi Qinghua Decoction on Gut Microbiota, Intestinal Permeability and Glycolipid Metabolism in Newly Diagnosed T2DM Patients: Study Protocol for a Randomized, Double-blind, Placebo-controlled Clinical Trial
View through CrossRef
Abstract
BackgroundThe gut microbiome is a key target for traditional Chinese medicines (TCM) to ameliorate type 2 diabetes mellitus (T2DM). Patients with T2DM have quite distinct gut microbiota in comparisons with normal individuals, and it directly influences intestinal permeability. This study aims to investigate the underlying effects of Jianpi Qinghua Decoction on gut microbiota and intestinal permeability in newly diagnosed T2DM patients.Methods / designThis study is a single-center, randomized, double-blind, placebo-controlled clinical trial in 120 subjects with newly diagnosed T2DM. The patients will be randomized in a 1:1 ratio into placebo group (1/10 Jianpi Qinghua Decoction + maltodextrin twice daily, n = 60) and treatment group (Jianpi Qinghua Decoction twice daily, n = 60). The study drugs will be double blinded to both investigators and participants. The visits will be done at baseline (visit 0), 1 month (visit 1), 2 months (visit 2), 3 months (visit 3). Measures include: anthropometric measures, blood pressure, glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-hour postprandial blood glucose (2hPG) and serum insulin, total cholesterol (TC), total triglycerides (TG), low-density lipoprotein cholesterol (LDL) and high-density lipoprotein cholesterol (HDL), safety indexs (including blood routine examination, clinical urine tests, liver/renal profile), identifying intestinal permeability used ELISA testing serum LPS, serum intestinal fatty acid binding protein (IFABP), serum Zonulin concentrations and fecal sample collection for gut microbiota profiling through 16S rRNA gene sequencing. Data will be analyzed using SPSS version 26. DiscussionWe describe a clinical research protocol evaluating the impact of Jianpi Qinghua Decoction on gut microbiota and intestinal permeability in newly diagnosed T2DM patients. We assume that adminstration of Jianpi Qinghua Decoction will correct gut microbial dysbiosis and intestinal permeability, leading to improved glycemic control.Trial registrationChinese clinical trial registry, identifier: ChiCTR2000039423(http://www.chictr.org.cn/edit.aspx?pid=62537&htm=4.).Registered on 27 October 2020.
Springer Science and Business Media LLC
Title: Effect of Jianpi Qinghua Decoction on Gut Microbiota, Intestinal Permeability and Glycolipid Metabolism in Newly Diagnosed T2DM Patients: Study Protocol for a Randomized, Double-blind, Placebo-controlled Clinical Trial
Description:
Abstract
BackgroundThe gut microbiome is a key target for traditional Chinese medicines (TCM) to ameliorate type 2 diabetes mellitus (T2DM).
Patients with T2DM have quite distinct gut microbiota in comparisons with normal individuals, and it directly influences intestinal permeability.
This study aims to investigate the underlying effects of Jianpi Qinghua Decoction on gut microbiota and intestinal permeability in newly diagnosed T2DM patients.
Methods / designThis study is a single-center, randomized, double-blind, placebo-controlled clinical trial in 120 subjects with newly diagnosed T2DM.
The patients will be randomized in a 1:1 ratio into placebo group (1/10 Jianpi Qinghua Decoction + maltodextrin twice daily, n = 60) and treatment group (Jianpi Qinghua Decoction twice daily, n = 60).
The study drugs will be double blinded to both investigators and participants.
The visits will be done at baseline (visit 0), 1 month (visit 1), 2 months (visit 2), 3 months (visit 3).
Measures include: anthropometric measures, blood pressure, glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-hour postprandial blood glucose (2hPG) and serum insulin, total cholesterol (TC), total triglycerides (TG), low-density lipoprotein cholesterol (LDL) and high-density lipoprotein cholesterol (HDL), safety indexs (including blood routine examination, clinical urine tests, liver/renal profile), identifying intestinal permeability used ELISA testing serum LPS, serum intestinal fatty acid binding protein (IFABP), serum Zonulin concentrations and fecal sample collection for gut microbiota profiling through 16S rRNA gene sequencing.
Data will be analyzed using SPSS version 26.
DiscussionWe describe a clinical research protocol evaluating the impact of Jianpi Qinghua Decoction on gut microbiota and intestinal permeability in newly diagnosed T2DM patients.
We assume that adminstration of Jianpi Qinghua Decoction will correct gut microbial dysbiosis and intestinal permeability, leading to improved glycemic control.
Trial registrationChinese clinical trial registry, identifier: ChiCTR2000039423(http://www.
chictr.
org.
cn/edit.
aspx?pid=62537&htm=4.
).
Registered on 27 October 2020.
Related Results
IMPACT OF GUT MICROBIOTA ON POSTOPERATIVE RECOVERY AND WOUND HEALING
IMPACT OF GUT MICROBIOTA ON POSTOPERATIVE RECOVERY AND WOUND HEALING
The gut microbiota, made up of trillions of microorganisms that inhabit the gastrointestinal tract, plays a fundamental role in human health, influencing immunological and metaboli...
Procedure for Latex beads coating with glycolipids v1
Procedure for Latex beads coating with glycolipids v1
Goal: This document aims to standardize the protocol for latex beads coating with the Mycobacterium leprae phenolic glycolipid “PGL I”. Beads-PGL I coating is used, for example, fo...
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Radical prostatectomy is the most commonly performed treatment option for localised prostate cancer. In the last decades the surgical technique has been improved and modified in or...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
GW24-e2123 Effect of Sini Decoction on the expression of Sirt-1 and eNOS system in EAhy926 cells injured by homocysteine
GW24-e2123 Effect of Sini Decoction on the expression of Sirt-1 and eNOS system in EAhy926 cells injured by homocysteine
Objectives
To detect the effect of Sini Decoction on the expression of Sirt-1 and eNOS in EAhy926 cell injured by homocysteine.
...
Clinical research for the significance of inflammatory factors and adiponectin in type 2 diabetes complicated with non-alcoholic fatty liver disease
Clinical research for the significance of inflammatory factors and adiponectin in type 2 diabetes complicated with non-alcoholic fatty liver disease
Objective
To investigate the clinical significance of inflammatory factors and adiponectin in type 2 diabetes milletus complicated with non-alcoholic fatty liver ...
Differential response of digesta- and mucosa-associated intestinal microbiota to dietary insect meal during the seawater phase of Atlantic salmon
Differential response of digesta- and mucosa-associated intestinal microbiota to dietary insect meal during the seawater phase of Atlantic salmon
Abstract
Background: Intestinal digesta is commonly used for studying responses of microbiota to dietary shifts, yet evidence is accumulating that it represents an incomple...
Causal relationship between gut microbiota and malignant lymphoma:a two-way two-sample Mendelian randomization study
Causal relationship between gut microbiota and malignant lymphoma:a two-way two-sample Mendelian randomization study
Abstract
Background
The significance of gut microbiota in human health is gaining attention, leading to a rise in observational and clinical studies focused on understandi...

